Trial Profile
Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs KPAX 002 (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Therapeutic Use
- Acronyms Synergy; The Synergy Trial
- Sponsors K-PAX Pharmaceuticals
- 24 Apr 2018 Results presented in the K-PAX Pharmaceuticals media release.
- 07 Oct 2015 New trial record
- 21 Sep 2015 Status changed from active, no longer recruiting to completed according to a K-PAX Pharmaceuticals media release.